ArticleClinical pharmacology : advances and applications2010
Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review.
Article in Clinical pharmacology : advances and applications, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Oxandrolone for growth hormone-treated girls aged up to 18 years with Turner syndrome.The Cochrane database of systematic reviews · 2019Pooled it
- Improvement in body composition of Japanese participants with Prader-Willi syndrome following somatropin treatment: an open-label, multi cohort Phase 3 study.Endocrine journal · 2025Trial
- Physician experience with once-weekly somatrogon versus once-daily rhGH regimen in pediatric patients with growth hormone deficiency: a cross-sectional survey of physicians from the global phase 3 study.Frontiers in endocrinology · 2023Trial
- Stem cell therapy alleviates hair loss caused by COVID-19 vaccination.Journal of exercise rehabilitation · 2026Article
- A single-cell transcriptomic landscape characterizes the endocrine system aging in the mouse.Protein & cell · 2026Article
- Quality of life and treatment burden of children receiving daily growth hormone treatment in Greece.Endocrine · 2025Article
- A Recurrent Mutation in Growth Hormone Receptor (The Yale journal of biology and medicine · 2023Article
- Treatment burden, adherence, and quality of life in children with daily GH treatment in France.Endocrine connections · 2023Article
- Evaluating the TUITEKFrontiers in endocrinology · 2023Article
- Treatment Burden of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Randomized Study.Journal of the Endocrine Society · 2022Article
- Characterization and expression of DNA sequences encoding the growth hormone gene in African Pygmy Mouse (Mus minutoides).The Journal of veterinary medical science · 2021Article
- Targeting Energy Expenditure-Drugs for Obesity Treatment.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Tissue-specific disruption of the growth hormone receptor (GHR) in mice: An update.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2020Review
- Exploring Potentially Modifiable Factors That Influence Treatment Non-Adherence Amongst Pediatric Growth Hormone Deficiency: A Qualitative Study.Patient preference and adherence · 2020Article
- Hypermobility in individuals with Kabuki syndrome: The effect of growth hormone treatment.American journal of medical genetics. Part A · 2019Article
- Growth Hormone Receptor Mutations Related to Individual Dwarfism.International journal of molecular sciences · 2018Review
- A follow-up study to monitor adult height among Spanish children with growth hormone deficiency who received biosimilar human recombinant growth hormone (Omnitrope®) during a phase III clinical trial.Advances in therapy · 2015Observational
- The patient with Turner syndrome: puberty and medical management concerns.Fertility and sterility · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growth hormone (GH), also known as somatotropin, is a peptide hormone that is synthesized and secreted by the somatotrophs of the anterior pituitary gland. The main action of GH is to stimulate linear growth in children; however, it also fosters a healthy body composition by increasing muscle and reducing fat mass, maintains normal blood glucose levels, and promotes a favorable lipid profile. This article provides an overview of the normal pathophysiology of GH production and action. We discuss the history of GH therapy and the development of the current formulation of recombinant human GH given as daily subcutaneous injections. This paper reviews two of the longest standing FDA-approved indications for GH treatment, GH deficiency and Turner syndrome. We will highlight the pathogenesis of these disorders, including presentations, presumed mechanism(s) for the associated short stature, and diagnostic criteria, with a review of stimulation test benefits and pitfalls. This review also includes current recommendations for GH therapy to help maximize final height in these children, as well as data demonstrating the efficacy and safety of GH treatment in these populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.